Navigation Links
Rigel Announces Participation at Two Investor Conferences
Date:2/9/2011

SOUTH SAN FRANCISCO, Calif., Feb. 9, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to participate at two investor conferences in New York City next week. Details of the events are as follows:Tuesday, February 15 at 9:00 a.m. ET13th Annual BIO CEO & Investor ConferencePanel Topic:  "Rheumatoid Arthritis: the Real Joint Problem"Tuesday, February 15 at 3:30 p.m. ET13th Annual BIO CEO & Investor ConferenceRigel Company Presentation (webcast)Thursday, February 17 at 7:45 a.m. ETLeerink Swann Hot Topics in Therapeutics Roundtable ConferencePanel Topic:  "Rheumatology"The company presentation at BIO CEO will be webcast live and can be accessed at www.rigel.com.  Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for RA (partnered with AstraZeneca), and R343, an inhaled syk inhibitor that is in clinical trials for asthma (partnered with Pfizer).

Contact: Ryan MaynardPhone: 650.624.1284Email:

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
(Date:9/19/2014)... Sept. 19, 2014  CytRx Corporation (Nasdaq: ... in oncology, today announced that David J. Haen ... 2014 NewsMakers in the Biotech Industry Conference on Friday, September ... conference will take place at the Millennium Broadway Hotel ... A live and archived webcast of the presentation ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... U.S. Food and Drug Administration is warning the public ... law enforcement personnel as part of a continued international ... The criminals call the victims -- who ... or via "telepharmacies" -- and identify themselves as FDA ...
... EDDA Technology, a leading provider of advanced computer ... successful commercial installation of its IQQA®-Liver Enterprise product ... one of the top performing living donor liver ... use EDDA Technology,s IQQA®-Liver Enterprise in conjunction with ...
Cached Medicine Technology:FDA Warns Public of Continued Extortion Scam By FDA Impersonators 2FDA Warns Public of Continued Extortion Scam By FDA Impersonators 3EDDA Technology Successfully Installs IQQA®-Liver at Mayo Clinic in Arizona 2
(Date:9/19/2014)... Forest Hills, NY (PRWEB) September 20, 2014 ... Periodontist Prabha Krishnan DMD in Queens, NY now reminds area ... “With more than 80% of our population affected by gum ... problem any longer.” , For over 20 years Dr. Krishnan ... her Forest Hills office location. “Most patients that come in ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Recently, ... and announced that JustHost, IX Web Hosting and ... , “As is known to most people, ... partitioning a physical server computer into many servers, ... of running on someone’s own dedicated computer,” the ...
(Date:9/19/2014)... proteins and large protein complexes are notoriously difficult to ... often very difficult, if not impossible, to crystallize, but ... flexible. The result is that when a structure can ... and reveals a mosaic-like spread of protein domains that ... & Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
(Date:9/19/2014)... September 19, 2014 Top10BestSEOHosting.com today ... announces that HostMonster, Arvixe and Bluehost are the ... buy high quality WordPress hosting (including VPS and ... websites for more detailed information. , HostMonster ( ... high-powered service at a fraction of the cost. ...
(Date:9/19/2014)... Texas (PRWEB) September 19, 2014 Singulair, ... the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs ... from a variety of cells, including mast cells and ... receptors. Several studies have determined that there are higher ... asthmatics compared with non-asthmatic individuals. The production of CysLTs ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4
... the University of Florida have initiated a project to ... secrets of regeneration from creatures with remarkable powers of ... ,Fueled by about $6 million in private donations, university ... connect scientists who work with adult human stem cells ...
... seventeen patients have been dead due to the infection of ... have died after contracting Clostridium Difficile, commonly known as C ... also reported that few of the patients were infected with ... strain. Major bowel surgery had to be performed on five ...
... the FDA launched a special Web page. This web page ... isotretinoin, sold by Roche// under the brand name Accutane, on ... acne that is not controlled by other treatment forms. FDA ... and severe mental health problems. ,The FDA warning ...
... the cancer drugs to be given freely to patients. They ... 1// and appealed to Northern Ireland's new assembly to follow ... diagnosed with cancer every year. Heather Monteverde from the charity ... as it causes a huge financial burden on them. ...
... at Birmingham's Magnetic Source Imaging Laboratory are studying the ... to learn more about the intricacies of brain pathology. ... the geography of the brain or detect blood flow, ... throw off as they communicate. "You can look at ...
... was shortened as Calgaria. But this has failed to soothe ... insult those afflicted by mental sickness. ,“I realize ... those of us living with mental illness who have to ... who suffers from depression and sits on the board for ...
Cached Medicine News:Health News:UF Launches Project to Bridge the Regeneration Gap 2Health News:UF Launches Project to Bridge the Regeneration Gap 3Health News:Web Page to Warn Against Online Purchase of Isotretinoin 2Health News:MEG Scanners Are Mega Powerful 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... (RAM) is the first visual examination device that ... in eyes with glaucoma, cataract, and macular disease. ... test each eye easily in under 60 seconds. ... Columbia University in New York City, the RAM ...
Medicine Products: